Kopp, Sabrina; Tilch, Marie-Kristin; Sagoschen, Ingo et al.
A rare case of right heart failure with the necessity for veno-arterial extracorporeal membrane oxygenation following pulmonary vein stenosis after radiofrequency ablation for atrial fibrillationPULMONARY CIRCULATION. Bd. 13. H. 1. 2023
Jentschke, Elisabeth; Roch, Carmen; Reinholz, Ulrike et al.
Acute confusional states and delirium in palliative careONKOLOGIE. 2023
Berning, Philipp; Schmitz, Norbert; Ngoya, Maud et al.
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysisLEUKEMIA. 2023
Urmann, Emanuel; Stamm, Paul; Wisskirchen, Jonas
Cefiderocol in AML patient with neutropenic infection due to 4MRGN Klebsiella pneumoniae (VIM-1)DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT. Bd. 148. H. 04. 2023 S. 170-174
Mackensen, Andreas; Haanen, John B. A. G.; Koenecke, Christian et al.
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trialNATURE MEDICINE. 2023
Novak, Urban; Fehr, Martin; Schaer, Saemi et al.
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)ECLINICALMEDICINE. Bd. 64. 2023
Albendea, Miguel A. Canales; Canonico, Pier Luigi; Cartron, Guillaume et al.
Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countriesFRONTIERS IN MEDICINE. Bd. 10. 2023
Duque-Afonso, Jesus; Finke, Juergen; Ngoya, Maud et al.
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working PartyBONE MARROW TRANSPLANTATION. 2023
Pielenhofer, JS; Meiser, L; Gogoll, K et al.
Complaint management of a quality defect in a nanoparticulate Imiquimod formulation in an investigator initiated academic phase I/II clinical trial Part 1Pharmazeutische Industrie. Bd. 85. 2023 S. 182-6
Pielenhofer, JS; Meiser, L; Gogoll, K et al.
Complaint management of a quality defect in a nanoparticulate imiquimod formulation in an investigator initiated academic phase I/II clinical trial, part 2Pharmazeutische Industrie. Bd. 85. 2023 S. 294-299